Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Shigeki Shibasaki"'
Autor:
Ikumi Tamai, Kazuhiko Kato, Erika Kuraoka, Hisashi Suzuki, Akihiro Kikuchi, Shigeki Shibasaki, Yoshiyuki Shirasaka, Maki Iguchi, Tohru Kurosawa
Publikováno v:
Molecular Pharmaceutics. 7:1747-1756
Tebipenem pivoxil (TBPM-PI) is an oral carbapenem antibiotic for treating otolaryngologic and respiratory infections in pediatric patients. This agent is a prodrug to improve intestinal absorption of TBPM, an active form, and an absorption rate of TB
Autor:
Makoto Aoki, Masahiro Hayashi, Hiroyuki Hayashi, Shigeki Shibasaki, Maki Iguchi, Tohru Kurosawa
Publikováno v:
Biological & Pharmaceutical Bulletin. 32:1095-1100
Ulifloxacin is a new quinolone antibiotic and it is effective against pneumonia. We previously showed that it is highly distributed into the epithelial lining fluid (ELF) in rats, which might be resulting from certain active transport. The transport
Autor:
Hiroyuki Hayashi, Tohru Kurosawa, Shigeki Shibasaki, Kyoichi Totsuka, Nayu Mitomi, Jun Morita, Tomokazu Koresawa, Koji Kijima, Hisashi Suzuki, Nobuo Sato
Publikováno v:
Drug Metabolism and Pharmacokinetics. 23:434-446
Tebipenem pivoxil (TBPM-PI, ME1211) has been under development as the world's first oral carbapenem for treatment of otolaryngological/respiratory infections caused by drug-resistant S. pneumoniae in pediatric patients. In order to treat these infect
Autor:
Hisashi Suzuki, Hiroyuki Hayashi, Shigeki Shibasaki, Maki Iguchi, Makoto Aoki, Tohru Kurosawa, Masahiro Hayashi
Publikováno v:
Biological and Pharmaceutical Bulletin. 31:1773-1777
Microdialysis method (MD) is useful for sampling protein-unbound substances in vivo. Generally in the MD, a reference compound is used to correct differences in drug permeation clearance through a dialysis membrane in vivo and in vitro. No reference
Autor:
Tohru Kurosawa, Shigeki Shibasaki, Kouichi Yoshinari, Masahiro Nomoto, Frank J. Gonzalez, Yasuhiro Shindo, Miki Shimada, Yasushi Yamazoe, Masaaki Miyata
Publikováno v:
European Journal of Pharmacology. 574:192-200
ME3738 (22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol), a derivative of soyasapogenol, attenuates liver disease in several models of chronic liver inflammation. In the present study, we have investigated a protective effect of ME3738 in a typical
Autor:
Tohru Kurosawa, Yukihiro Yagi, Yukio Kato, Akira Tsuji, Shigeki Shibasaki, Makoto Aoki, Maki Iguchi
Publikováno v:
Drug Metabolism and Pharmacokinetics. 22:350-357
Summary: Prulifloxacin (PUFX) is a prodrug-type new quinolone antibiotic and immediately converted to an active metabolite, ulifloxacin (UFX). It has been previously reported that UFX is highly excreted into the bile, although the hepatic uptake proc
Autor:
Shigeki Shibasaki, Izumi Komiya
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 31:255-260
Cerebrospinal fluid (CSF) concentrations of quinolone antibiotics in humans, which may be related to CNS adverse effects and quinolone antibiotic-induced convulsions, were predicted from parameters for penetration into the CSF (CSF-to-unbound plasma
Protective Effect of Inactive Ingredients against Nephrotoxicity of Vancomycin Hydrochloride in Rats
Autor:
Shigeki Shibasaki, Yoshihisa Nakano, Nayu Mitomi, Akiko Gyobu, Naoko Hodoshima, Masaaki Izumi, Toru Kurosawa, Yukari Nakamura, Makoto Aoki
Publikováno v:
Drug Metabolism and Pharmacokinetics. 19:68-75
A generic form of vancomycin for I.V. infusion (MEEK) is more soluble and stable than the brand-name form of vancomycin hydrochloride (VCM) due to the addition of two inactive ingredients: D-mannitol and Macrogol400 (PEG400). The aim of the present s
Publikováno v:
The Japanese journal of antibiotics. 67(1)
Population pharmacokinetic analysis was conducted on cefditoren pivoxil (CDTR-PI), a third generation oral antibiotic to evaluate the effect of covariates on pharmacokinetic parameters. Plasma concentrations of cefditoren (CDTR, total number of sampl
Publikováno v:
The Japanese journal of antibiotics. 67(1)
The objective of this study was to predict the clinical bacteriological efficacy of antibiotics and to examine the pharmacodynamics (PD) characteristics of antibiotics against bacterial strains using a mechanism-based pharmacokinetic-pharmacodynamics